Sequent Scientific merger scheme receives NCLT approval

On November 20, 2025, Sequent Scientific Limited announced the receipt of the National Company Law Tribunal's (NCLT) certified order dated November 18, 2025, approving its composite scheme of amalgamation. The scheme involves Sequent Scientific Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited.

The amalgamation scheme, with an appointed date of April 1, 2025, will see the transfer of assets and liabilities of Transferor Companies 1 to 5 to Transferee Company 1, Transferor Company 6 to Transferee Company 2, and Transferor Company 7 to Transferee Company 1, among other mergers. The scheme was approved by the board of directors of all petitioner companies on September 26, 2024.

Share exchange ratios include 47 equity shares of Transferee Company 1 for every one fully paid-up equity share of Transferor Company 7. For the amalgamation of Amalgamating Company 1 into Amalgamated Company, 56 equity shares of the Amalgamated Company (at a face value of INR 2 each) will be issued for every 100 fully paid-up equity shares of Amalgamating Company 1 (at a face value of INR 10 each). Warrant holders will also receive 56 share warrants for every 100 existing warrants, with a warrant price of Rs.181.94 per Amalgamated Company Warrant.